Holen Sie sich die Stockscreener-App
12.56
0.56%
0.07
Handel nachbörslich:
12.56
Contineum Therapeutics Inc Aktie (CTNM) Neueste Nachrichten
J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next? - Yahoo Finance
Wall Street Analysts Are Bullish on Top Healthcare Picks - theglobeandmail.com
Goldman Sachs initiates coverage on Contineum Therapeutics stock By Investing.com - Investing.com Nigeria
Goldman Sachs initiates coverage on Contineum Therapeutics stock - Investing.com
RBC Capital Sticks to Their Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail
RBC Cuts Price Target on Contineum Therapeutics to $21 From $23, Keeps Outperform, Speculative Risk - marketscreener.com
Contineum Therapeutics, Inc.(NasdaqGS:CTNM) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Definium Therapeutics (DFTX) - theglobeandmail.com
LifeSci Capital Maintains Contineum Therapeutics(CTNM.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Precision Trading with Contineum Therapeutics Inc. (CTNM) Risk Zones - Stock Traders Daily
CTNM Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 5.32%Revenue Guidance Range - careplusvn.com
Contineum Therapeutics Tumbles After Depression Drug Misses Primary Goal in Phase 2 - finance.biggo.com
Contineum fails in MDD; Definium’s LSD prospect nears NDA - bioworld.com
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails - Yahoo Finance
JonesTrading Maintains Contineum Therapeutics(CTNM.US) With Buy Rating, Cuts Target Price to $24 - Moomoo
Stifel maintains Buy on Contineum stock after phase 2 trial miss - Investing.com Canada
Contineum’s depression drug trial fails primary endpoint By Investing.com - Investing.com India
Contineum Therapeutics Shares Fall After Drug Trial Missed Primary Endpoint - marketscreener.com
Contineum Therapeutics Reports Phase 2 MOONLIGHT-1 Results - TipRanks
Contineum Therapeutics stock falls on phase 2 trial miss By Investing.com - Investing.com Australia
Contineum, J&J's depression drug fails to meet mid-stage trial goal - marketscreener.com
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder - Yahoo Finance
Contineum Therapeutics CEO Stengone sells $41,141 in stock By Investing.com - Investing.com Canada
Contineum Therapeutics CEO Stengone sells $41,141 in stock - Investing.com
Contineum (CTNM) CEO sells shares under preset plan - Stock Titan
Carmine Stengone to sell 2,500 Contineum (CTNM) shares - Stock Titan
Technical Reactions to CTNM Trends in Macro Strategies - Stock Traders Daily
Show Me The Money: Contineum Therapeutics' Turnaround From Lows To New Highs - RTTNews
RBC Capital Maintains Contineum Therapeutics(CTNM.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Contineum Therapeutics (CTNM) Climbs 1.91% as Shares Hold Above Key SupportWyckoff Accumulation - vinanet.vn
Officer at Contineum (NASDAQ: CTNM) lines up new stock sale - Stock Titan
Behavioral Patterns of CTNM and Institutional Flows - Stock Traders Daily
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet - qz.com
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference - The Chronicle-Journal
Contineum (CTNM) Chart: Records a 7.30% Increase to $17.19 for the Current Session - vinanet.vn
Contineum (CTNM) Chart: Records a 7.30% Increase to $17.19 for the Current Session; Chart View: the Current Price Sits Inside the Supplied Technical Range in the Available RecordVolatility Breakout Picks - siam.in
Balyasny Asset Management L.P. Expands Stake in Contineum Therap - GuruFocus
Contineum (CTNM) Results at a Glance: The Bottom-Line Figure Beats Its Comparison in Latest Trading; Closing Move - vinanet.vn
Morgan Stanley Adjusts PT on Contineum Therapeutics to $18 From $16, Keeps Equalweight Rating - marketscreener.com
Contineum Therapeutics, Inc. Stock 12‑Month Price Target Raised to $23.14, Implies 63% Upside - TradingView
Contineum Therapeutics (CTNM) Slides 7.25% to $14.19 — Testing Key Support After Sharp Sell-OffFair Value Gap - vinanet.vn
Stifel Maintains Contineum Therapeutics(CTNM.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Contineum Therapeutics (NASDAQ:CTNM) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Contineum Therapeutics (NASDAQ:CTNM) Trading Down 4.9%What's Next? - marketbeat.com
Contineum Therapeutics (CTNM): Balyasny group reports 7.14% stake in 13G/A filing - Stock Titan
Contineum Therapeutics (NASDAQ:CTNM) Trading 6.8% HigherShould You Buy? - MarketBeat
CTNM Q2 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Share GainCFO Commentary Report - Vinanet
CTNM Q2 2026 Earnings: Narrower-than-Expected Loss Lifts SharesGross Profit Margin - Vinanet
Contineum Therapeutics (CTNM) Pulls Back 3.66% to $14.49 as Support Level Comes into FocusZero Lag EMA - dars.gov.et
(CTNM) Risk Channels and Responsive Allocation - Stock Traders Daily
Form 4 Contineum Therapeutics Inc For: 3 August By Investing.com - Investing.com Nigeria
Contineum Therapeutics CEO Stengone sells $40,029 of common stock By Investing.com - Investing.com Nigeria
Contineum Therapeutics (CTNM) CEO sells 2,500 shares after option exercise - Stock Titan
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):